Non-invasive ventilation nursing: BiPAP, CPAP, and NIV management

Non-invasive ventilation (NIV) delivers positive-pressure respiratory support through a mask interface rather than an endotracheal tube. It is one of the most impactful interventions in acute care: a well-timed trial of NIV can prevent intubation, reduce ICU length of stay, and lower mortality in select patient populations. For nursing students and new graduates, mastering NIV means understanding the difference between BiPAP and CPAP, knowing exactly who benefits from each mode, recognizing the early signs of NIV failure, and providing the hands-on care – mask fit, skin protection, patient coaching – that determines whether a trial succeeds or fails.

This guide covers the full clinical picture: indications, contraindications, interface selection, pressure settings, nursing monitoring, failure criteria, and NCLEX-specific traps. For patients who progress beyond NIV, see the mechanical ventilation nursing guide. For background on oxygen delivery systems, see the oxygen therapy nursing guide. ABG interpretation is covered in detail in the ABG interpretation guide.

BiPAP vs CPAP: the core distinction

BiPAP and CPAP are both forms of NIV but they work through different mechanisms and treat different problems. Confusing the two is a common source of NCLEX errors.

CPAP delivers one fixed pressure throughout the entire respiratory cycle – both during inhalation and exhalation. It does not assist the patient’s inspiratory effort; it simply maintains a constant pneumatic splint that keeps the airway open and recruits collapsed alveoli. The pressure keeps alveoli from closing at end-expiration, improving oxygenation and reducing the work of breathing against a collapsed airway. CPAP is the preferred modality for obstructive sleep apnea (OSA) and cardiogenic pulmonary edema.

BiPAP delivers two distinct pressures: a higher inspiratory positive airway pressure (IPAP) triggered when the patient begins to inhale, and a lower expiratory positive airway pressure (EPAP) that remains during exhalation. The IPAP actively augments each breath, increasing tidal volume and allowing CO2 elimination. The EPAP functions the same as PEEP in mechanical ventilation – it keeps alveoli open between breaths. BiPAP is the preferred modality for hypercapnic (Type II) respiratory failure, where the patient needs help with ventilation, not just oxygenation.

The pressure support delivered is the difference between IPAP and EPAP. A BiPAP set at IPAP 14 / EPAP 6 delivers 8 cmH2O of pressure support per breath. In COPD exacerbation that is a starting point, and the British Thoracic Society/Intensive Care Society (BTS/ICS) guideline notes that national audits repeatedly found IPAP set too low – insufficient pressure support is one of the commonest reasons NIV fails.

Indications for NIV

COPD exacerbation (hypercapnic respiratory failure)

This is the best-evidenced indication for BiPAP. Patients with acute COPD exacerbation develop Type II respiratory failure – pH falls, PaCO2 rises, and they tire rapidly from increased work of breathing against dynamic hyperinflation. BiPAP augments each breath, reduces respiratory muscle fatigue, and corrects respiratory acidosis.

A specific pH triggers BiPAP. The 2017 ERS/ATS clinical practice guideline makes its single strongest, highest-certainty recommendation here: bilevel NIV for acute or acute-on-chronic respiratory acidosis with pH ≤ 7.35 due to COPD exacerbation, after optimal medical therapy (bronchodilators, steroids, controlled oxygen to a target SpO2 of 88–92%). The pooled effect is large: mortality relative risk 0.63 and intubation relative risk 0.41 against standard care. The same guideline recommends against NIV in COPD patients who are hypercapnic but not acidotic, so a normal pH with a raised PaCO2 is not by itself an indication. The BTS/ICS guideline adds a practical point: in around 20% of these patients, optimal medical therapy with oxygen titrated to 88–92% corrects the acidosis on its own, so NIV is started when pH below 7.35 with PaCO2 above 6.5 kPa (about 49 mmHg) persists or develops despite that therapy. There is no lower pH limit below which a trial becomes inappropriate; the lower the pH, the higher the failure risk, and the more the patient needs a monitored bed with immediate access to intubation. See the COPD nursing guide for the full exacerbation management picture and the acute respiratory failure guide for Type I vs Type II classification.

Cardiogenic pulmonary edema

Flash pulmonary edema from acute decompensated heart failure floods the alveoli, causing severe hypoxemia. Positive pressure drives fluid from the alveoli back into the vasculature, reduces venous return (preload), lowers left ventricular wall stress (afterload), and improves oxygenation rapidly – often within 30–60 minutes. CPAP at 5–10 cmH2O is the usual starting point, largely because it is simpler to set up and widely available in emergency departments and prehospital services.

CPAP and BiPAP are equivalent here, and older teaching that ranks one above the other is out of date. The 2017 ERS/ATS guideline recommends either bilevel NIV or CPAP for cardiogenic pulmonary edema (strong recommendation, moderate certainty). The 3CPO trial, the largest randomized trial in this population at 1,069 patients, found no significant difference between CPAP and bilevel in death or intubation at seven days (11.7% versus 11.1%), and no short-term mortality benefit for either against standard oxygen therapy – though both produced faster improvement in dyspnea, heart rate, acidosis, and hypercapnia at one hour. The 2019 Cochrane review of 24 trials does find reduced hospital mortality and reduced intubation against standard medical care, pooling CPAP and bilevel together rather than separating them. Practically: pick the modality your unit is set up for, and choose bilevel when the patient is also hypercapnic or tiring. For the full heart failure picture see the heart failure nursing guide.

Obstructive sleep apnea

CPAP is the definitive therapy for OSA. It maintains upper airway patency throughout sleep, preventing the repetitive apneic episodes that fragment sleep and cause nocturnal hypoxemia. Nursing students encounter home CPAP patients in acute care settings; these patients should use their own CPAP equipment when hospitalized and it should be documented on the medication administration record.

Immunocompromised patients with hypoxemia

Patients who are immunocompromised – from hematologic malignancy, solid organ transplant, or high-dose corticosteroids – face dramatically higher infection risk with endotracheal intubation, particularly ventilator-associated pneumonia (VAP). A trial of NIV to avoid intubation is clinically important in this population. The ERS/ATS guideline suggests early NIV here (conditional recommendation, moderate certainty), with pooled reductions in mortality, intubation, and nosocomial pneumonia. Later evidence has made the picture less clear. The largest randomized trial in this group (Lemiale 2015, 374 patients, mostly with cancer) found no mortality difference between early NIV and oxygen alone (24.1% versus 27.3% at day 28) and no difference in ICU-acquired infections. In a post hoc analysis of the 82 immunocompromised patients in the FLORALI trial, intubation was required in 65% of those given NIV, against 31% with high-flow nasal cannula alone, and the authors advised caution with first-line NIV. The choice between NIV and high-flow nasal cannula in this group is unsettled, and either way the patient needs close monitoring. If NIV fails, intubation should proceed promptly; delayed intubation after a failing trial is associated with higher mortality.

Obese hypoventilation syndrome (OHS)

OHS combines obesity (BMI > 30) with daytime hypercapnia (PaCO2 > 45 mmHg) not attributable to another cause. Patients typically present with somnolence, polycythemia, and right heart strain. In acute hypercapnic respiratory failure, BiPAP addresses both components – the hypoxemia via EPAP and the hypoventilation via IPAP-driven tidal volume augmentation – and these patients often need higher pressures than COPD patients (BTS/ICS cites IPAP above 30 and EPAP above 8 cmH2O as common). Long-term management differs: the 2019 American Thoracic Society OHS guideline suggests CPAP rather than bilevel NIV as first-line therapy for stable outpatients with OHS and coexisting severe obstructive sleep apnea, and suggests discharging patients hospitalized with suspected OHS on NIV until outpatient sleep testing and titration are done.

Contraindications to NIV

Textbooks and exam items usually present a long list of contraindications. The BTS/ICS guideline points out that most of them were trial exclusion criteria rather than proven causes of harm, and states that there are few absolute contraindications to a trial of NIV. Most of the features below are better treated as high-risk features: they raise the chance of failure and call for an HDU/ICU bed, closer monitoring, and staff who can intubate immediately. The clear-cut cases for intubation instead of NIV are respiratory arrest or peri-arrest and situations where no interface can be fitted.

Interface selection

The mask interface determines patient comfort, leak management, and ultimately the success of a NIV trial. Match the interface to the clinical situation and the patient’s anatomy.

Full face (oronasal) mask – covers both nose and mouth. The standard interface for acute care NIV. Prevents air leak through the mouth, tolerates higher pressures, and is the most practical choice when patients are mouth-breathing from dyspnea. The primary disadvantage is claustrophobia and the inability to eat, drink, or speak with the mask on. This is the interface you will see in most hospital acute NIV trials.

Nasal mask – covers the nose only. Widely used for chronic home NIV (COPD, OHS, OSA). Lower claustrophobia burden and allows speech. Problematic in acute care because severely dyspneic patients mouth-breathe, causing large air leaks that defeat the pressure delivery.

Nasal pillows – soft cushions that seal at the nares. Preferred by many home OSA patients for comfort. Rarely suitable for acute NIV: mouth leak limits all nasal interfaces, and pillows are more easily dislodged than a full face mask.

Total face mask – a clear shield that seals around the entire face, including the eyes. BTS/ICS describes it as useful when air leak stays excessive with a standard mask or when nasal bridge ulceration develops, and it is sometimes better tolerated by confused or agitated patients.

Helmet NIV – a transparent hood that encloses the entire head with a seal at the neck. Used mainly in specialist centers. It avoids facial skin contact, but triggering is less effective, it can be noisy, and gases cannot be humidified. In a single-center trial of 83 patients with ARDS (Patel 2016), switching from face mask to helmet NIV cut the intubation rate from 61.5% to 18.2%, a result that still needs confirmation in larger trials.

Typical pressure settings and titration

Initial settings are based on the clinical indication. The goal is the minimum pressure that achieves the therapeutic target – unnecessary pressure increases patient discomfort and leak.

CPAP starting settings: Begin at 5–8 cmH2O. Titrate upward by 2 cmH2O increments to maintain SpO2 at target (≥ 90%) and reduce work of breathing. Maximum effective range is approximately 10–15 cmH2O. For cardiogenic pulmonary edema, 5–10 cmH2O is typical.

BiPAP starting settings: Starting points vary by protocol; IPAP 10–15 with EPAP 4–5 cmH2O is common. In COPD exacerbation, the BTS/ICS guideline advises starting at an IPAP around 15 and increasing it progressively to 20–30 cmH2O within 10–30 minutes, faster in more severe acidosis and higher in larger patients. Titrate toward visible chest and abdominal wall movement with each breath, a falling RR, and correcting hypercapnia (rising pH, falling PaCO2 on ABG). EPAP must be at least 3 cmH2O to flush exhaled CO2 from the mask; it is raised mainly for persistent hypoxemia or upper airway obstruction. Most acute NIV is delivered in spontaneous/timed (S/T) mode, in which the prescriber sets a backup rate: if the patient breathes slower than that rate, the machine delivers timed breaths.

Monitoring targets after initiation:

• SpO2 88–92% in hypercapnic respiratory failure of any cause (BTS/ICS), or the prescribed range – typically 94–98% for other acutely ill adults (BTS 2017)
• RR falling within 1–2 hours
• pH improving toward ≥ 7.35 on ABG
• PaCO2 trending down (in hypercapnic patients)
• Patient comfort and cooperation
• Reduced use of accessory muscles

Oxygen and pressure are separate dials. In hypercapnic failure, BTS/ICS advises optimizing the NIV settings before increasing FiO2, because better alveolar ventilation improves oxygenation too. Oxygen should be entrained as close to the mask as possible, and a ventilator with an integral oxygen blender is recommended when 4 L/min of entrained oxygen fails to keep SpO2 above 88%; higher entrained flows add little and can worsen leak and triggering.

Nursing monitoring during NIV

Check and document all parameters every 30–60 minutes during the first few hours of NIV initiation. Once stable, monitoring frequency can extend based on unit protocol and patient acuity.

NIV failure: recognition and escalation

The first 1–2 hours of NIV are the critical window. If the patient is responding, you will see measurable improvement: SpO2 rising, RR falling, accessory muscle use decreasing, patient looking less distressed, and ABGs improving. Absence of these signs – or deterioration – defines NIV failure.

In COPD, the BTS/ICS guideline notes that persisting pH below 7.25 with RR above 35 makes failure likely, and that worsening acidosis after initial improvement carries a poor prognosis. Before calling the trial a failure, check the common technical causes the guideline lists: excessive mask leak, too little pressure support, and patient–ventilator asynchrony.

In hypoxemic (Type I) failure, NIV fails more often and the warning signs are different. In Antonelli’s multicenter study, 30% of hypoxemic patients failed NIV overall, rising to about half of those with ARDS or community-acquired pneumonia, against 10% with cardiogenic pulmonary edema; a PaO2/FiO2 ratio still at or below 146 after 1 hour predicted failure. Two bedside tools are worth knowing. The HACOR score (heart rate, acidosis, consciousness, oxygenation, respiratory rate) above 5 after 1 hour of NIV predicted failure with about 90% specificity in its validation study, and among those patients, intubation within 12 hours was associated with lower mortality than later intubation. Large expired tidal volumes are another warning sign: in Carteaux’s cohort, an expired tidal volume above 9.5 mL/kg predicted body weight predicted failure in patients with a PaO2/FiO2 of 200 or less.

A failed NIV trial does not mean NIV was wrong to try. A 1–2 hour trial with clear escalation criteria is the standard approach. The risk lies in recognizing failure late – do not wait until the patient is in extremis before calling the provider.

Skin breakdown prevention

Pressure injury from the mask interface is common during extended NIV use. The nasal bridge is the highest-risk site because it bears the most mask contact force. Prevention is a nursing responsibility and should start before the first skin breakdown appears.

Prevention strategies:

• Apply a thin foam barrier dressing (hydrocolloid or foam) to the nasal bridge before mask application and replace at each interface check
• Inspect skin every 2–4 hours; document findings
• Rotate between interface types when clinically possible (for example, alternating full face mask with nasal mask during periods of lower acuity or during brief breaks)
• Apply moisture barrier cream to areas at risk for maceration from sweat and humidity
• Ensure the mask is as loose as possible while still maintaining an adequate seal – overtightening accelerates skin breakdown without improving seal significantly
• Ask about mouth and nasal dryness: BTS/ICS does not require routine humidification in acute NIV, but heated humidification should be considered when the patient reports mucosal dryness or secretions are thick and hard to clear

Patient education and comfort management

A cooperative patient is the most important determinant of NIV success outside of the clinical indication itself. Patients who understand what the mask will feel like and why it is helping are significantly more likely to tolerate it.

Before mask application:

• Explain the purpose in plain language: “This mask will help you breathe with less effort and give you more oxygen without needing a breathing tube.”
• Describe the sensation: “It will feel like air pushing in when you breathe in. It may feel strange at first but most people get used to it within a few minutes.”
• Show the patient the mask before applying it

During NIV:

• Stay with the patient during the first 10–15 minutes of initiation – this is when tolerance is established or abandoned
• Give clear, calm verbal coaching: “Breathe with the machine. Let it help you. Don’t fight it.”
• If the patient is claustrophobic, holding the mask loosely against their face (not strapped) for the first minute or two can reduce panic before the headgear is secured
• Check for patient–ventilator asynchrony before attributing agitation to anxiety alone; BTS/ICS recommends considering it in every agitated patient
• Administer sedation only if ordered and with close monitoring, because it can depress respiratory drive. BTS/ICS suggests IV morphine 2.5–5 mg (with or without a benzodiazepine) may relieve distress and improve tolerance, and limits infused sedatives to HDU or ICU settings
• Address pain, if present – pain from rib fractures or abdominal distension reduces cooperation dramatically

Breaks from NIV:

• Oral hygiene, eating (if tolerated), and brief communication breaks are permitted in stable patients
• Document the duration of each break – total NIV hours per shift matters clinically
• During breaks, provide appropriate supplemental oxygen via face mask or nasal cannula

NCLEX tips: non-invasive ventilation

1. BiPAP delivers two pressures; CPAP delivers one. IPAP assists inspiration; EPAP maintains airway patency. CPAP has no inspiratory assist – it is a single fixed pressure.

2. BiPAP is first-line for COPD exacerbation with respiratory acidosis, pH ≤ 7.35. This is the number to memorize. The evidence is robust: BiPAP reduces intubation rates and mortality in Type II respiratory failure. Hypercapnia without acidosis is not an indication – the ERS/ATS guideline recommends against NIV in that situation.

3. For cardiogenic pulmonary edema, either CPAP or BiPAP is appropriate. Positive pressure reduces preload and afterload, rapidly improving oxygenation. CPAP is the more common starting choice on practical grounds, but the ERS/ATS guideline recommends either modality and the 3CPO trial found no outcome difference between them. Exam items written before 2017 may still frame CPAP as the only right answer.

4. NIV does NOT replace intubation in respiratory arrest. A patient who is apneic or in respiratory arrest requires immediate bag-mask ventilation and emergent intubation. NIV requires the patient to be breathing.

5. NIV is not used in a patient who cannot protect their airway. An absent gag reflex or inability to cooperate makes aspiration and failure likely, and exam items treat these as contraindications. The exception to know: drowsiness from CO2 narcosis in a COPD exacerbation is a reason to start NIV in a closely monitored bed, because mentation often improves as PaCO2 falls.

6. The IPAP/EPAP pressure difference = pressure support. IPAP 14 / EPAP 6 delivers 8 cmH2O of pressure support. This is what augments tidal volume and drives CO2 elimination.

7. Mask-related problems are the most frequent NIV complications. Discomfort, facial redness, and nasal bridge pressure injury are common and largely preventable: avoid overtightening and apply foam dressings prophylactically, before damage appears.

8. An ABG at 1–2 hours is the key NIV failure assessment tool. Clinical improvement alone is not sufficient – pH and PaCO2 must be trending in the right direction.

9. Watch for mucosal dryness. Humidification is not routinely required in acute NIV (BTS/ICS), but heated humidification should be considered when the patient reports dryness or has thick secretions, because discomfort undermines tolerance.

10. CPAP at 5–10 cmH2O for cardiogenic edema; BiPAP for COPD starts around IPAP 10–15 / EPAP 4–5 and is titrated up. The BTS/ICS guideline advises reaching an IPAP of 20–30 cmH2O within 10–30 minutes in COPD, and too little IPAP is a common reason NIV fails.

11. Rising RR + worsening WOB + no ABG improvement = NIV failure. This combination at 1–2 hours means you must escalate immediately.

12. Avoiding intubation is the rationale for NIV in immunocompromised patients. Intubation carries a high infection risk in this group, and ERS/ATS suggests early NIV. The later Lemiale trial found no mortality benefit over oxygen alone, though, so high-flow nasal cannula is a common alternative and close monitoring matters more than the device.

13. Full face mask is the standard acute care interface – covers nose and mouth, prevents leak during mouth-breathing, tolerates higher pressures.

14. Undrained pneumothorax is a contraindication to NIV. Positive pressure can convert a simple pneumothorax into a life-threatening tension pneumothorax.

15. For COPD patients, target SpO2 88–92%, not 94–98%. Excessive oxygen in chronic hypercapnic COPD worsens CO2 retention; in Austin’s prehospital trial, oxygen titrated to 88–92% cut mortality by 58% overall against high-flow oxygen (4% versus 9%). Note the mechanism: BTS 2017 (section 6.3.1) ranks release of hypoxic pulmonary vasoconstriction, which worsens ventilation-perfusion matching and increases dead space, as the main cause. Reduced respiratory (“hypoxic”) drive comes second and makes only a small contribution, followed by the Haldane effect, in which oxygenated hemoglobin releases CO2 into plasma. Some NCLEX items still test the older hypoxic-drive framing, so recognize the phrase, but the 88–92% target itself is the clinically important part.

16. An ARDS patient typically requires intubation, not NIV alone. NIV failure rates are high in ARDS because the degree of shunt physiology does not respond sufficiently to non-invasive pressure delivery. See the ARDS nursing guide for lung-protective ventilation strategy.

17. The backup rate on BiPAP protects against apnea and slow breathing. In spontaneous/timed (S/T) mode, the mode most often used for acute hypercapnic failure, the machine delivers timed breaths whenever the patient’s own rate falls below the set backup rate.

18. Declining mental status during NIV is an escalation trigger, not a reason to try a higher pressure. If GCS is dropping, airway protection is the clinical priority – call the provider.

Putting it together

NIV works when the right patient gets the right modality at the right time. COPD exacerbation with a pH of 7.28 and rising PaCO2 on a BiPAP trial has decades of evidence behind it. Flash pulmonary edema turning around within 45 minutes of CPAP initiation is one of the most satisfying acute interventions in medicine. The nurse’s role is not only to apply the equipment but to assess whether it is working, keep the patient comfortable and cooperative enough to sustain the trial, protect the skin, and recognize early enough when the patient is failing so that escalation to mechanical ventilation happens before the patient deteriorates further.

Use the ABG interpretation guide to interpret serial blood gases during NIV trials and understand whether respiratory acidosis is correcting. For the classification of Type I vs Type II respiratory failure that determines which NIV modality is appropriate, see the acute respiratory failure guide.

Written by Lindsay Smith, AGPCNP. Reviewed for clinical accuracy and NCLEX alignment.

References

1. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1995;333(13):817–822. doi:10.1056/NEJM199509283331301
2. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet. 2000;355(9219):1931–1935. doi:10.1016/S0140-6736(00)02323-0
3. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008;359(2):142–151. doi:10.1056/NEJMoa0707992
4. Berbenetz N, Wang Y, Brown J, et al. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev. 2019;(4):CD005351. doi:10.1002/14651858.CD005351.pub4
5. Davidson AC, Banham S, Elliott M, et al. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults. Thorax. 2016;71(Suppl 2):ii1–ii35. doi:10.1136/thoraxjnl-2015-208209
6. Nava S, Hill N. Non-invasive ventilation in acute respiratory failure. Lancet. 2009;374(9685):250–259. doi:10.1016/S0140-6736(09)60496-7
7. Antonelli M, Conti G, Rocco M, et al. A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. N Engl J Med. 1998;339(7):429–435. doi:10.1056/NEJM199808133390703
8. Carron M, Freo U, BaHammam AS, et al. Complications of non-invasive ventilation techniques: a comprehensive qualitative review of randomized trials. Br J Anaesth. 2013;110(6):896–914. doi:10.1093/bja/aet070
9. Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med. 2001;163(2):540–577. doi:10.1164/ajrccm.163.2.9906116
10. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis, and Management of COPD: 2026 Report. Version 1.3, December 2025. Available at: https://goldcopd.org
11. Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50(2):1602426. doi:10.1183/13993003.02426-2016
12. Duan J, Han X, Bai L, Zhou L, Huang S. Assessment of heart rate, acidosis, consciousness, oxygenation, and respiratory rate to predict noninvasive ventilation failure in hypoxemic patients. Intensive Care Med. 2017;43(2):192–199. doi:10.1007/s00134-016-4601-3
13. Antonelli M, Conti G, Moro ML, et al. Predictors of failure of noninvasive positive pressure ventilation in patients with acute hypoxemic respiratory failure: a multi-center study. Intensive Care Med. 2001;27(11):1718–1728. doi:10.1007/s00134-001-1114-4
14. Carteaux G, Millán-Guilarte T, De Prost N, et al. Failure of noninvasive ventilation for de novo acute hypoxemic respiratory failure: role of tidal volume. Crit Care Med. 2016;44(2):282–290. doi:10.1097/CCM.0000000000001379
15. Patel BK, Wolfe KS, Pohlman AS, Hall JB, Kress JP. Effect of noninvasive ventilation delivered by helmet vs face mask on the rate of endotracheal intubation in patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA. 2016;315(22):2435–2441. doi:10.1001/jama.2016.6338
16. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185–2196. doi:10.1056/NEJMoa1503326
17. Abdo WF, Heunks LMA. Oxygen-induced hypercapnia in COPD: myths and facts. Crit Care. 2012;16(5):323. doi:10.1186/cc11475
18. Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010;341:c5462. doi:10.1136/bmj.c5462
19. Lemiale V, Mokart D, Resche-Rigon M, et al. Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA. 2015;314(16):1711–1719. doi:10.1001/jama.2015.12402
20. Frat JP, Ragot S, Girault C, et al. Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trial. Lancet Respir Med. 2016;4(8):646–652. doi:10.1016/S2213-2600(16)30093-5
21. Mokhlesi B, Masa JF, Brozek JL, et al. Evaluation and management of obesity hypoventilation syndrome: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2019;200(3):e6–e24. doi:10.1164/rccm.201905-1071ST
22. O’Driscoll BR, Howard LS, Earis J, Mak V. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017;72(Suppl 1):ii1–ii90. doi:10.1136/thoraxjnl-2016-209729